Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
Now insiders say J&J has decided it is no longer interested.
The surprising disclosure was outlined in a November 2017 letter from the FDA.
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
The company struck the cash-and-share deals to boost its presence in Europe.
News of the buy was tucked away in the company’s fourth-quarter financial report.
This acquisition strategy is part of its two-pronged approach to growth, along with internal R&D.
The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people.
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
Here are five possible acquisition targets to keep an eye on.